Avenue Therapeutics, Inc. (ATXI)

NASDAQ: ATXI · IEX Real-Time Price · USD
0.130
0.00 (0.08%)
At close: Apr 22, 2024, 4:00 PM
0.133
+0.003 (2.31%)
After-hours: Apr 22, 2024, 6:46 PM EDT
0.08%
Market Cap 5.76M
Revenue (ttm) n/a
Net Income (ttm) -10.38M
Shares Out 44.26M
EPS (ttm) -0.98
PE Ratio n/a
Forward PE 17.99
Dividend n/a
Ex-Dividend Date n/a
Volume 1,602,025
Open 0.130
Previous Close 0.130
Day's Range 0.114 - 0.138
52-Week Range 0.113 - 1.250
Beta -0.26
Analysts Strong Buy
Price Target 0.75 (+476.48%)
Earnings Date May 10, 2024

About ATXI

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 27, 2017
Employees 3
Stock Exchange NASDAQ
Ticker Symbol ATXI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for ATXI stock is "Strong Buy" and the 12-month stock price forecast is $0.75.

Price Target
$0.75
(476.48% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of t...

4 weeks ago - GlobeNewsWire

Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights

- Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 -

5 weeks ago - GlobeNewsWire

Avenue Therapeutics Receives Positive Listing Determination from Nasdaq

MIAMI, March 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of t...

5 weeks ago - GlobeNewsWire

Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting

BAER-101 demonstrated full suppression of seizure activity in SynapCell's GAERS model of absence epilepsy, a proven indicator of efficacy in anti-seizure drug development with high predictability of r...

6 weeks ago - GlobeNewsWire

Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy

-In vivo data supports BAER-101's unique ability to significantly suppress seizures using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg (“GAERS”) model of absence epilepsy- -In vivo dat...

2 months ago - GlobeNewsWire

Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference

MIAMI, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of th...

3 months ago - GlobeNewsWire

Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds

MIAMI, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of th...

3 months ago - GlobeNewsWire

Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol

MIAMI, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of th...

3 months ago - GlobeNewsWire

Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

- Topline data remains on track for second quarter of 2024 - MIAMI, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical c...

3 months ago - GlobeNewsWire

Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting

MIAMI, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of th...

5 months ago - GlobeNewsWire

Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

- Phase 1b/2a clinical trial of AJ201 remains on track to report topline data in second quarter of 2024 - - Positive BAER-101 preclinical data accepted for presentation at American Epilepsy Society (A...

5 months ago - GlobeNewsWire

Avenue Therapeutics Announces Closing of $5.0 Million Public Offering

MIAMI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of th...

6 months ago - GlobeNewsWire

Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering

MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of th...

6 months ago - GlobeNewsWire

Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

MIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of t...

8 months ago - GlobeNewsWire

Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

- First patient dosed in Phase 1b/2a clinical trial of AJ201; topline data anticipated in first half of 2024 - - Positive BAER-101 preclinical data demonstrate excellent anti-seizure activity in trans...

9 months ago - GlobeNewsWire

Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study

-A Phase 2a study of BAER-101 in epilepsy is planned to initiate in 2024 -A Phase 2a study of BAER-101 in epilepsy is planned to initiate in 2024

9 months ago - GlobeNewsWire

Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

MIAMI, July 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of th...

9 months ago - GlobeNewsWire

Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol

MIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of th...

9 months ago - GlobeNewsWire

Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

MIAMI, May 12, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of the...

1 year ago - GlobeNewsWire

Avenue Therapeutics to Present at Aegis Capital Virtual Conference

MIAMI, April 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of t...

1 year ago - GlobeNewsWire

Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol

MIAMI, April 17, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of t...

1 year ago - GlobeNewsWire

Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights

MIAMI, March 30, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of t...

1 year ago - GlobeNewsWire

Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates

Company to participate in Type C meeting for IV Tramadol with FDA on March 9, 2023 Company to participate in Type C meeting for IV Tramadol with FDA on March 9, 2023

1 year ago - GlobeNewsWire

Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy

AJ201 is being evaluated in a Phase 1b/2a clinical trial in the U.S. for the rare X-linked genetic neurodegenerative disease also known as Kennedy's Disease which currently has no FDA approved therapy...

1 year ago - GlobeNewsWire

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI)

NEW YORK, NY / ACCESSWIRE / January 31, 2023 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATX...

Other symbols: FBIO
1 year ago - Accesswire